Serialization and the Drug Quality & Security Act

The supply chain for genuine pharmaceuticals has grown longer, and every step in the chain offers an opportunity for counterfeiters.

Bikash Chatterjee, president and CTO, Pharmatech Associates
supplychainsupernav

The problem of counterfeit drugs and drug adulteration has been a worldwide issue for decades. Fueled by Internet sales, unsecured physical and cyber global supply chains and minimal punishments, counterfeit prescription drugs have become an exploding industry, with an estimated market worth $75 billion a year worldwide¹. An estimated 80 percent of counterfeit drugs come from overseas with most of them manufactured in India and China. In this era of globalization, the supply chain for genuine pharmaceuticals has grown longer, and every step in the chain offers another opportunity for counterfeiters. The challenges facing drug manufacturers are numerous in addressing the…

Full Story

Don't Miss These Pharma Manufacturing Exclusives

Fundamentals

On-demand, concise audio and powerpoint tutorials on the fundamental concepts of a range of pharmaceutical manufacturing, process development quality control and compliance topics.

Ask the Expert

We've assembled a roster of leading authorities in many fields to help you address technical issues. Pose a question or browse previous questions to find helpful answers.

Funny Pharm

Write a caption and win!

jan15homeBe sure to check out our newest cartoon created by award-winning artist Jerry King. He provides the artwork; you provide the funny caption!

Most Recent

  • Serialization and the Drug Quality & Security Act

    By Bikash Chatterjee, president and CTO, Pharmatech Associates

    The problem of counterfeit drugs and drug adulteration has been a worldwide issue for decades. Fueled by Internet sales, unsecured physical and cyber global supply chains and minimal punishments, counterfeit prescription drugs have become an exploding industry, with an estimated market worth $75…

    Full Story
  • Biotech’s Riding the Polar Express

    By Edward S. Price, President, PCI Synthesis

    The biotech sector is one that knows extremes: We’re seeing a biotech bubble at the same time we’re seeing companies squeezed out by rising costs and fees necessary to just stay in business. Pressures, including regulatory and dwindling competition, are driving price increases among generics…

    Full Story
  • Integrated Continuous Manufacturing

    By Salvatore Mascia and Bernhardt Trout, CONTINUUS Pharmaceuticals

    Pharmaceutical manufacturing has been performed using batch technologies for more than a century. While most other manufacturing industries use continuous operations combined with advanced process control and automation, the pharmaceutical industry has mostly relied on fixed recipes to produce…

    Full Story
  • Challenges and Opportunities of Cost-Effective and Affordable Biosimilars

    By Daniel N. Galbraith PhD, Chief Scientific Officer

    This post originally appeared on the BioOutsource blog Biosimilars challenge us in many ways; these issues can be divided into three groups: challenges faced by scientists, challenges faced by industry and challenges faced by patients. In my job, as a CSO working in Contract Research, I have found…

    Full Story
  • Top Stirs and Scandals of 2014

    Valeant's Not-So-Valiant Pursuit of Allergan In April, when Canada's Valeant Pharmaceuticals and activist hedge fund manager Bill Ackman made an unsolicited $47 billion bid for Allergan, analysts predicted a "complicated hostile takeover deal that may not happen at all" -- and they were spot on.

    Full Story
  • Top Industry Shake-Ups (and Shakedowns) of 2014

       Novartis Makes $27B+ Worth of Deals with GSK, Lilly April 2014 Novartis launched the long-awaited business restructuring, with several multibillion-dollar deals with GlaxoSmithKline and Eli Lilly & Co. The deals include: • Novartis will buy GSK’s Oncology business for $14.5 billion…

    Full Story

Latest Products